Physician profile
Brian D Witt
NPI 1952628646
$18,993.39
in general payments reported to CMS, 2019-2025
40 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $140 · 2021: $55.06 · 2022: $8,326 · 2023: $1,349 · 2024: $7,315 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,300 · Food and Beverage: $4,056 · Travel and Lodging: $1,034 · Education: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,300.00 |
| Food and Beverage | $4,056.49 |
| Travel and Lodging | $1,034.35 |
| Education | $576.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,971.57 | 2022-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $1,566.54 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $534.37 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| United Therapeutics Corporation | $526.33 | 2019-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.02 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $258.84 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $257.08 | 2022-2024 | Dupixent |
| Grifols USA, LLC | $197.67 | 2019-2025 | Prolastin-C Liquid |
| Electromed, INC. | $95.16 | 2019-2025 | Smartvest |
| Amgen INC. | $92.97 | 2019-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $91.11 | 2023-2025 | Zerbaxa, Recarbrio |
| Abbvie INC. | $89.56 | 2023-2025 | Teflaro |
| Mylan Specialty L.P. | $89.46 | 2019-2024 | Yupelri |
| Pfizer INC. | $85.83 | 2019-2025 | |
| Harmony Biosciences LLC | $68.85 | 2023-2025 | Wakix |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Witt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.